These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

697 related articles for article (PubMed ID: 33355048)

  • 21. Metformin monotherapy for type 2 diabetes mellitus.
    Saenz A; Fernandez-Esteban I; Mataix A; Ausejo M; Roque M; Moher D
    Cochrane Database Syst Rev; 2005 Jul; (3):CD002966. PubMed ID: 16034881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J
    Am J Cardiol; 2017 Jul; 120(1S):S4-S16. PubMed ID: 28606343
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm.
    Bailey T
    Am J Med; 2013 Sep; 126(9 Suppl 1):S10-20. PubMed ID: 23953074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metformin: clinical use in type 2 diabetes.
    Sanchez-Rangel E; Inzucchi SE
    Diabetologia; 2017 Sep; 60(9):1586-1593. PubMed ID: 28770321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metformin: old wine in new bottle--evolving technology and therapy in diabetes.
    Joshi SR
    J Assoc Physicians India; 2005 Nov; 53():963-72. PubMed ID: 16515237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of diabetes in metabolic syndrome].
    Pelikánova T
    Vnitr Lek; 2009; 55(7-8):637-45. PubMed ID: 19731868
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective.
    Charokopou M; McEwan P; Lister S; Callan L; Bergenheim K; Tolley K; Postema R; Townsend R; Roudaut M
    BMC Health Serv Res; 2015 Nov; 15():496. PubMed ID: 26541516
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metformin therapy and clinical uses.
    Scarpello JH; Howlett HC
    Diab Vasc Dis Res; 2008 Sep; 5(3):157-67. PubMed ID: 18777488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
    Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
    Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C.
    Harris K; Smith L
    Ann Pharmacother; 2013 Oct; 47(10):1348-52. PubMed ID: 24259699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.
    Liu Y; Hong T
    Diabetes Obes Metab; 2014 Feb; 16(2):111-7. PubMed ID: 23668534
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Current role of metformin in treatment of diabetes mellitus type 2].
    Janssen JA
    Ned Tijdschr Geneeskd; 2000 Sep; 144(40):1900-2. PubMed ID: 11045135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
    Paneni F; Lüscher TF
    Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cardiovascular effects of metformin: further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus.
    Anfossi G; Russo I; Bonomo K; Trovati M
    Curr Vasc Pharmacol; 2010 May; 8(3):327-37. PubMed ID: 19485923
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acarbose plus metformin fixed-dose combination in the management of type 2 diabetes.
    Joshi SR; Ramachandran A; Chadha M; Chatterjee S; Rathod R; Kalra S
    Expert Opin Pharmacother; 2014 Aug; 15(11):1611-20. PubMed ID: 24963542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dapagliflozin combination therapy in type 2 diabetes mellitus.
    Yacoub T
    Postgrad Med; 2016 Jan; 128(1):124-36. PubMed ID: 26571022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Understanding the inter-relationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model.
    McEwan P; Evans M; Kan H; Bergenheim K
    Diabetes Obes Metab; 2010 May; 12(5):431-6. PubMed ID: 20415691
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A pre-specified statistical analysis plan for the VERIFY study: Vildagliptin efficacy in combination with metformin for early treatment of T2DM.
    Matthews DR; Paldánius PM; Stumvoll M; Han J; Bader G; Chiang Y; Proot P; Del Prato S
    Diabetes Obes Metab; 2019 Oct; 21(10):2240-2247. PubMed ID: 31144427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain.
    Shearer AT; Bagust A; Ampudia-Blasco FJ; Martínez-Lage Alvarez B; Pérez Escolano I; París G
    Pharmacoeconomics; 2006; 24 Suppl 1():49-59. PubMed ID: 16800162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.